ArticleOncoTargets and therapy2017

miR182 activates the Ras-MEK-ERK pathway in human oral cavity squamous cell carcinoma by suppressing RASA1 and SPRED1.

Jinhui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.